Navigation Links
GeoPharma Announces Record Revenues in Third Quarter Results
Date:2/14/2008

inistrative expenses, exclusive of depreciation

and amortization, were $5.3 million for the quarter ended December 2007

as compared to $3.7 million for the quarter ended September 2007.

Increases this quarter were attributable to higher costs related to the

addition of the DYHP acquisition in October 2007 in addition to

additional legal and accounting costs and other business expansion such

as rents, payrolls and related insurances.

-- Research and development ("R&D") expenditures for the three months

ended December 31, 2007 totaled approximately $310,000 all of which was

charged as an expense to operations as compared to $336,000 of R&D

expense for September 2007.

CONFERENCE CALL INFORMATION

GeoPharma will host a conference call to discuss results on Thursday, February 14, 2008 at 11:30 (ET) with CEO, Mihir Taneja and VP/CFO, Carol Dore-Falcone. Interested parties may participate in the conference call by dialing 1-888-680-0869 and entering pass code 78555682, 5 minutes prior to the initiation of the call. A replay of the conference call will be available from 1:30 PM (ET) on February 14 through February 21, by dialing 1-888-286-8010 and entering pass code 37538422.

Webcast registration (http://phx.corporate- ir.net/phoenix.zhtml?c=120778&p=IROL-Guestbook&UniqueId=1754335&mp=irol- eventDetails&mpdp=EventId~1754335!WebCastId~724916!StreamId~1051110&pp=IROL - BasicWebCast&ppdp=EventId~1754335!WebCastId~724916!StreamId~1051110&pph=339 &pp w=270&rdu)

ABOUT GEOPHARMA, INC.:

GeoPharma, Inc. is a rapidly growing Bio/Pharma company with a diversified business model participating in 3 main market segments: Specialty Pharma, Manufacturing, and Distribution. The Specialty Pharma division specializes in the formulation of generic drugs for human and veterinary usage and the development of medical devices used
'/>"/>

SOURCE GeoPharma, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related biology technology :

1. GeoPharma Announces Third Quarter Conference Call
2. GeoPharma, Inc. Receives FDA Approval to Manufacture and Distribute Carprofen
3. Angiotech announces results for the fourth quarter ended December 31, 2007
4. Cell Therapeutics, Inc. (CTI) Announces Cancellation of Approximately $9.1 Million of Existing Notes due 2008
5. Warner Chilcott Announces Earnings Release Date and Conference Call for Fourth Quarter and Full Year 2007 Financial Results
6. Jazz Pharmaceuticals, Inc. Announces Fourth Quarter and Full Year 2007 Financial Results
7. NightHawk Radiology Holdings, Inc. Announces Senior Executive Departures
8. VLST Corporation Announces Board and Executive Management Appointments
9. Advance Nanotech Announces Shareholder Proxy Vote Results
10. Cellegy Pharmaceuticals Announces Signing of Definitive Merger Agreement
11. Halogen Announces Record Year - Company Solidifies Leadership Position, Secures Strategic Wins Over Competition
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/29/2014)... 2014 /PRNewswire/ - iCo Therapeutics ("iCo" or "the ... results for the six months ended June 30, ... Canadian dollars and presented under International Financial Reporting ... , Announced top-line results related to ... for subjects enrolled in the Phase 2 iDEAL ...
(Date:8/29/2014)... 29, 2014 A major challenge before ... start-up dense realm of Boston-Cambridge, is gaining visibility that ... James Sherley, the Director of Boston’s Adult Stem Cell ... and national visibility of his company an important priority ... In addition to a social media marketing campaign ...
(Date:8/28/2014)... 28, 2014 Best Sanitizers, Inc., the ... alcohol-based hand sanitizer, asks food processors and food handling ... hand sanitizer they’re currently using to Best Sanitizers’ ... is critical to fighting cross-contamination and the spread of ... believes there are key criteria that make a hand ...
(Date:8/28/2014)... , Aug. 28, 2014 ... a new market research report ... Whole Exome Sequencing ... (Library Preparation, Target Enrichment), by ... by Synthesis), by Application (Cancer, ...
Breaking Biology Technology:iCo Therapeutics Announces Second Quarter 2014 Financial Results 2iCo Therapeutics Announces Second Quarter 2014 Financial Results 3iCo Therapeutics Announces Second Quarter 2014 Financial Results 4The Adult Stem Cell Technology Center, LLC Participates in Multiple Stem Cell and Regenerative Medicine Conferences Before Year End 2The Adult Stem Cell Technology Center, LLC Participates in Multiple Stem Cell and Regenerative Medicine Conferences Before Year End 3The Adult Stem Cell Technology Center, LLC Participates in Multiple Stem Cell and Regenerative Medicine Conferences Before Year End 4Food Processors and Food Handlers are Encouraged to Prepare for Fall Harvest by Evaluating Their Current Hand Sanitizer Using Nine Key Criteria 2Food Processors and Food Handlers are Encouraged to Prepare for Fall Harvest by Evaluating Their Current Hand Sanitizer Using Nine Key Criteria 3Whole Exome Sequencing Market by Product (Systems, Kits (Library Preparation, Target Enrichment), by Services (Sequencing), by Technology (Sequencing by Synthesis), by Application (Cancer, Monogenic disorders) - Global Forecast to 2018 2Whole Exome Sequencing Market by Product (Systems, Kits (Library Preparation, Target Enrichment), by Services (Sequencing), by Technology (Sequencing by Synthesis), by Application (Cancer, Monogenic disorders) - Global Forecast to 2018 3Whole Exome Sequencing Market by Product (Systems, Kits (Library Preparation, Target Enrichment), by Services (Sequencing), by Technology (Sequencing by Synthesis), by Application (Cancer, Monogenic disorders) - Global Forecast to 2018 4Whole Exome Sequencing Market by Product (Systems, Kits (Library Preparation, Target Enrichment), by Services (Sequencing), by Technology (Sequencing by Synthesis), by Application (Cancer, Monogenic disorders) - Global Forecast to 2018 5Whole Exome Sequencing Market by Product (Systems, Kits (Library Preparation, Target Enrichment), by Services (Sequencing), by Technology (Sequencing by Synthesis), by Application (Cancer, Monogenic disorders) - Global Forecast to 2018 6Whole Exome Sequencing Market by Product (Systems, Kits (Library Preparation, Target Enrichment), by Services (Sequencing), by Technology (Sequencing by Synthesis), by Application (Cancer, Monogenic disorders) - Global Forecast to 2018 7Whole Exome Sequencing Market by Product (Systems, Kits (Library Preparation, Target Enrichment), by Services (Sequencing), by Technology (Sequencing by Synthesis), by Application (Cancer, Monogenic disorders) - Global Forecast to 2018 8Whole Exome Sequencing Market by Product (Systems, Kits (Library Preparation, Target Enrichment), by Services (Sequencing), by Technology (Sequencing by Synthesis), by Application (Cancer, Monogenic disorders) - Global Forecast to 2018 9Whole Exome Sequencing Market by Product (Systems, Kits (Library Preparation, Target Enrichment), by Services (Sequencing), by Technology (Sequencing by Synthesis), by Application (Cancer, Monogenic disorders) - Global Forecast to 2018 10Whole Exome Sequencing Market by Product (Systems, Kits (Library Preparation, Target Enrichment), by Services (Sequencing), by Technology (Sequencing by Synthesis), by Application (Cancer, Monogenic disorders) - Global Forecast to 2018 11Whole Exome Sequencing Market by Product (Systems, Kits (Library Preparation, Target Enrichment), by Services (Sequencing), by Technology (Sequencing by Synthesis), by Application (Cancer, Monogenic disorders) - Global Forecast to 2018 12Whole Exome Sequencing Market by Product (Systems, Kits (Library Preparation, Target Enrichment), by Services (Sequencing), by Technology (Sequencing by Synthesis), by Application (Cancer, Monogenic disorders) - Global Forecast to 2018 13
... (OTC Bulletin Board: CSBR), a development stage,biotechnology company, ... of the Head and Neck Cancer Research Division ... as Chairman of the Board,replacing James Martell who ... was appointed to serve on the Company,s Board ...
... data show preferential, activity of adecatumumab on inhibiting ... 169 patients treated with adecatumumab demonstrate an ... of immunogenicity of the antibody, BETHESDA, Md., Oct. 23 ... on the development of,novel, proprietary antibody-based products for the treatment ...
... 23 Coordinating and timing,activities is a top ... of clinical trials. Marketers, who have the,primary responsibility ... "worry about competitors stealing your thunder, but also ... states one,interviewed executive. According to a Best ...
Cached Biology Technology:Dr. David Sidransky Appointed Chairman of Champions Biotechnology, Inc. 2Dr. David Sidransky Appointed Chairman of Champions Biotechnology, Inc. 3Dr. David Sidransky Appointed Chairman of Champions Biotechnology, Inc. 4Micromet Data Presented at the International AACR-NCI-EORTC Conference Support the Development of Adecatumumab (MT201) in Earlier Stage Cancer Disease Settings 2Micromet Data Presented at the International AACR-NCI-EORTC Conference Support the Development of Adecatumumab (MT201) in Earlier Stage Cancer Disease Settings 3Micromet Data Presented at the International AACR-NCI-EORTC Conference Support the Development of Adecatumumab (MT201) in Earlier Stage Cancer Disease Settings 4Micromet Data Presented at the International AACR-NCI-EORTC Conference Support the Development of Adecatumumab (MT201) in Earlier Stage Cancer Disease Settings 5Communicating Clinical Trial Data: Timing Remains Key Challenge for Marketing Teams 2
(Date:8/29/2014)... recently, little has been known about what genetic changes ... of scientists, one of whom is a University of ... that genes controlling the development of the brain and ... The study was published Aug. 28 in Science ... is online at http://www.sciencemag.org/ ., The domestication of ...
(Date:8/29/2014)... This news release is available in German . ... of chemical signals between organisms is considered the oldest ... social interactions between conspecifics, for example, the sexual attraction ... trigger social responses and to coordinate reproductive behavior in ... at the University of the Algarve in Faro, Portugal, ...
(Date:8/28/2014)... app called TX Invasives is now available from the ... Texas at Austin for identifying harmful non-native plant, insect ... in the United States cause about $137 billion in ... crops, clog waterways, kill native plants and more. , ... for reporting where invasive species occur, we,re more likely ...
Breaking Biology News(10 mins):New research reveals how wild rabbits were genetically transformed into tame rabbits 2New research reveals how wild rabbits were genetically transformed into tame rabbits 3Ready for mating at the right time 2Ready for mating at the right time 3Mobile app makes ID of harmful plants, insects in Texas a snap 2
... by researchers David General of the Palawan State University , ... Zoology , Harvard University has led to the discovery of nine ... Philippines. Another two new genera were discovered by other researchers in ... jubilee issue of the open access journal Zookeys ...
... of the site of a spent nuclear fuel repository ... the International Journal of Environmental Technology and Management, the ... positive opinion on the location of such facilities than ... of nuclear waste around the globe are relatively small, ...
... Spanish . , Project PreDiCT-TB is ... the European pharmaceutical industry in the hopes of studying ... that affects nearly nine million people throughout the world. ... trials (,in vitro, and ,in vivo,) that will provide ...
Cached Biology News:An ant scientist's picnic: The highly diverse ant fauna of the Philippines 2Where to put nuclear waste? 2Research on improvements in diagnosing and treating tuberculosis 2Research on improvements in diagnosing and treating tuberculosis 3
Fluorescein isothiocyanate (FITC) mouse anti-human IFN-alpha2 50 ug...
Rabbit Anti-melatonin (different linkage) Polyclonal Antibody...
Rabbit Anti-melatonin (different linkage) Polyclonal Antibody...
Anti-gamma Glutamyl Transferase (gammaGT) Host: mouse monoclonal Species Reactivity: human Applications: WB, IP, FC Storage: 4C...
Biology Products: